ADVM - アバランシェ・バイオテクノロジ―ズ (Adverum Biotechnologies Inc.)

ADVMのニュース

   Adverum Biotechnologies names new CMO  2022/02/07 21:16:40 Seeking Alpha
Adverum Biotechnologies (ADVM) has appointed ophthalmologist Richard Beckman, M.D., as the company''s new chief medical officer. Most recently, Dr
   Adverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical Officer  2022/02/07 21:05:00 GlobeNewswire
- Dr. Beckman, a board-certified ophthalmologist, brings 30 years of experience in ophthalmology, drug development and retinal diseases including wet age-related macular degeneration -
   Thinking about buying stock in Jaguar Health, Evofem Biosciences, Adverum Biotechnologies, FREYR Battery, or Planet Labs?  2022/01/12 13:35:00 Benzinga
NEW YORK , Jan. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, EVFM, ADVM, FREY, and PL. Full story available on Benzinga.com
   Adverum Biotechnologies Inc Shares Approach 52-Week Low - Market Mover  2022/01/10 06:53:01 Kwhen Finance
Adverum Biotechnologies Inc (ADVM) shares closed today at 1.2% above its 52 week low of $1.66, giving the company a market cap of $164M. The stock is currently down 4.5% year-to-date, down 85.9% over the past 12 months, and down 44.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 15.9% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 185.7% The company's stock price performance over the past 12 months lags the peer average by 185.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Adverum Biotechnologies Inc Shares Approach 52-Week Low - Market Mover  2022/01/08 13:01:48 Kwhen Finance
Adverum Biotechnologies Inc (ADVM) shares closed today at 1.2% above its 52 week low of $1.66, giving the company a market cap of $164M. The stock is currently down 4.5% year-to-date, down 86.0% over the past 12 months, and down 44.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 15.9% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 5.6% lower than its 5-day moving average, 7.0% lower than its 20-day moving average, and 18.3% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 442.5% The company's stock price performance over the past 12 months lags the peer average by 187.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Global Gene Therapy For Retinal Diseases Market | Applied Genetic Technologies Corporation, Adverum Biotechnologies, ProQR Therapeutics, MeiraGTx Limited., Oxford BioMedica, Horama S.A., Gensight Biologics, Regenxbio Inc., Spark Therapeutics, Inc., Genzym  2021/11/01 07:36:29 OpenPR
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the Global Gene Therapy For Retinal Diseases Market Trends, Industry Competition Analysis, Revenue and Forecast To 2030. Request for Sample Pages: https://www.insightaceanalytic.com/report/global-gene-therapy-for-retinal-diseases-market-/1157 According to the latest research study by
   Contrasting Adverum Biotechnologies (NASDAQ:ADVM) and IN8bio (NASDAQ:INAB)  2021/10/31 06:18:42 Dakota Financial News
Adverum Biotechnologies (NASDAQ:ADVM) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends. Earnings & Valuation This table compares Adverum Biotechnologies and IN8bios revenue, earnings per share and valuation. []
   Is It Safe To Invest In Adverum Biotechnologies Inc. (NASDAQ: ADVM) Now?  2021/10/29 13:30:00 Stocks Register
Adverum Biotechnologies Inc. (NASDAQ:ADVM) price on Thursday, October 28, rose 10.53% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.10. A look at the stock’s price movement, the close in the last trading session was $1.90, moving within a range at $1.90 and $2.13. The beta value … Is It Safe To Invest In Adverum Biotechnologies Inc. (NASDAQ: ADVM) Now? Read More »
   Enrapturing stocks: Adverum Biotechnologies, Inc. (NASDAQ:ADVM -3.10%), IT Tech Packaging, Inc. (AMEX:ITP -5.14%)  2021/10/23 00:53:18 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Enrapturing stocks: Adverum Biotechnologies, Inc. (NASDAQ:ADVM -3.10%), IT Tech Packaging, Inc. (AMEX:ITP -5.14%) appeared first on Stocks Equity .
   Analysts Expect Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Will Post Earnings of -$0.40 Per Share  2021/10/22 14:18:41 Dakota Financial News
Equities analysts expect Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to report earnings per share (EPS) of ($0.40) for the current quarter, Zacks reports. Zero analysts have made estimates for Adverum Biotechnologies earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.32). Adverum Biotechnologies reported earnings of ($0.31) per share during the same quarter last year, []
   Eye-popping stocks: Alibaba Group Holding Limited (NYSE:BABA -0.99%), Adverum Biotechnologies, Inc. (NASDAQ:ADVM -7.51%)  2021/09/06 22:20:02 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Eye-popping stocks: Alibaba Group Holding Limited (NYSE:BABA -0.99%), Adverum Biotechnologies, Inc. (NASDAQ:ADVM -7.51%) appeared first on Stocks Equity .
   Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs  2021/08/23 13:00:00 Intrado Digital Media
REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Jim Wang, Ph.D., has been appointed senior vice president, head of regulatory affairs. Reporting directly to Laurent Fischer, M.D., Adverums president and chief executive officer, Dr. Wang will lead regulatory strategies and execution for the companys product pipeline. He brings more than 17 years of global regulatory experience, including a decade in gene therapy that includes the submission and approval for LUXTURNA ® , the first gene therapy targeting a genetic disease that received regulatory approval in both the U.S. and EU.
   Global Alpha- Antitrypsin Deficiency Treatment Market 2026 Business Growth | Adverum Biotechnologies, IncAlnylam Pharmaceuticals, Inc.  2021/08/16 03:15:57 Jumbo News
LP INFORMATION recently released a research report on the Alpha- Antitrypsin Deficiency Treatment analysis, which studies the Alpha- Antitrypsin Deficiency Treatment industry coverage, current market competitive status, and market outlook and forecast by 2026. Global Alpha- Antitrypsin Deficiency Treatment Market 2021-2026 Research Report categorizes the global Alpha- Antitrypsin Deficiency Treatment by key players, product type, applications and regions,etc. The []
   Adverum Biotechnologies EPS misses by $0.07  2021/08/05 21:25:01 Seeking Alpha
   Bright Stock in Review: Adverum Biotechnologies, Inc. (NASDAQ:ADVM), ION Geophysical Corporation (NYSE:IO)  2021/08/03 22:53:20 Stock Equity
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) with the stream of -1.89% also noticed, India ION Geophysical Corporation (NYSE:IO) encountered a rapid change of -2.86% in the last hour of Tuesdays trading session. The post Bright Stock in Review: Adverum Biotechnologies, Inc. (NASDAQ:ADVM), ION Geophysical Corporation (NYSE:IO) appeared first on Stocks Equity .

calendar